Originally developed for type 2 diabetes management, several of these medications have received FDA approval for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with weight-related comorbidities
They also noted that patients who experienced moderate to severe gastrointestinal adverse events, like gastroparesis, were also more likely to discontinue GLP-1 use
SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition
Several serum studies have revealed decrease in the levels of plasma GSH levels in oral cancer [18]
This bidirectional axis integrates neural, immune, endocrine, and metabolic pathways, enabling gut microbes to influence mood, cognition, and behavior
Inhibition of XO activity generally leads to reduced production of uric acid (which itself is an AT)